Skip to: Content
Skip to: Site Navigation
Skip to: Search
THURSDAY, NOVEMBER 26, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter


0

Schizophrenia Drug Offers New Hope

Works on different brain chemical than its predecessors

Share

(Newser) – The first human trial of a new medication to treat schizophrenia that works fundamentally differently from its predecessors has shown promising results, according to this month's Nature Medicine. The drug targets glutamate rather than dopamine, as do other drugs. Scientists have long known glutamate is involved in schizophrenia.

The new drug alleviates symptom with few of the side effects of current anti-psychotics, such as tremors and weight gain. Drug manufacturer Eli Lilly plans to determine the optimal dosage for the medication before moving on to the final stage of testing and filing for FDA approval. Schizophrenia, which can involve delusions and hallucinations, affects 1% of the population, about the same as diabetes.

A women leaves the Eli Lilly and Company campus in an Indianapolis file photo from April 18, 2006.
A women leaves the Eli Lilly and Company campus in an Indianapolis file photo from April 18, 2006.   (Associated Press)
Medicine cabinet
Medicine cabinet   (KRT Photos)
Sue Voyles, daughter, Elena Ken Voyles and son, Ethan Voyles of Canton, Michigan. Like most families, the Voyles will deal with issues of health care in America.
Sue Voyles, daughter, Elena Ken Voyles and son, Ethan Voyles of Canton, Michigan. Like most families, the Voyles will deal with issues of health care in America.   (KRT Photos)
« Prev« Prev | Next »Next » Slideshow
OFF THE GRID
11.24.09
Murdoch and Microsoft: The Mice Are Trying to Roar
11.23.09
Books Are Bad for You
0 comments
VIEWING:
 
LEAVE A
COMMENT Comment Policy
Facebook ConnectPost this comment to Facebook?

After connecting you will have the option to post your comment on your Facebook profile.

 

Related Newser Stories

20 Stories

(Newser) - Mental health experts have lost touch with the benefits of old-fashioned insane asylums, where patients once enjoyed a sense of community and jobs like cleaning and farming, Oliver Sacks writes in the New York Review of Books. Touching on a new book of Christopher Payne photographs called Asylum—which offers... More »

MORE ABOUT:
schizophrenia • antipsychotic drugs • mental illness • asylum • mental hospital

FDA: Get Off Smell-Killing Zicam Nasal Spray, Now

Agency received over 130 reports of loss of smell sense

Jun 16, 09 12:47 PM CDT
(Newser) - The Food and Drug Administration is calling on consumers to stop using Zicam nasal treatments because they can permanently kill the sense of smell, the Wall Street Journal reports. Zicam is an over-the-counter cold and allergy medication sold in several forms; customers should reject internasal products that contain zinc. The... More »

MORE ABOUT:
medicine • FDA • pharmaceutical companies • drug safety • drug companies • smell • allergy • sense of smell • nasal passages • medication • cold • warning • Zicam • Matrixx

 Novartis Acquires Plavix Rival 

Novartis acquires worldwide rights from a San Francisco biopharmaceutical firm

Feb 12, 09 8:22 AM CST
(Newser) - Novartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the Wall Street Journal. Market leader Plavix rang up $8.22 billion... More »

MORE ABOUT:
pharmaceutical companies • Eli Lilly • Lipitor • prasugrel • Plavix • Bristol Myers Squibb • Novartis AG • Portola Pharmaceuticals • elinogrel

20 Stories


Study abstract (Full article requires subscription)
Nature

New drug could be the 'holy grail of drug development'
Bloomberg


Science & Health  •  Business  •  US 
TwitterFollow @NewserScience on Twitter

 
medicine • schizophrenia • pharmaceutical companies • antipsychotic drugs • dopamine • Eli Lilly • glutamate

from our news partners